论文部分内容阅读
目的:探究孟鲁司特钠联合复方异丙托溴铵治疗支气管哮喘的效果。方法:抽取2017年3月至2019年1月新乡市第一人民医院收治的支气管哮喘患者73例。根据随机数字表法分为观察组(38例)和对照组(35例)。对照组给予复方异丙托溴铵治疗，观察组在对照组治疗基础上联合孟鲁司特钠治疗。两组均治疗1个月，观察两组临床疗效、肺功能[1 s用力呼气容积(FEV1)、用力呼气肺活量(FVC)、最大呼气流量(PEF)、用力呼气肺活量1 s率(FEV1/FVC)]、血清白细胞介素-6(IL-6)水平。结果:观察组治疗总有效率(94.74%，36/38)高于对照组(74.29%，26/35)，差异有统计学意义(n P<0.05)。治疗后，观察组FEV1、FVC、PEF、FEV1/FVC均高于对照组，差异有统计学意义(n P<0.05)。治疗后，观察组IL-6水平低于对照组，差异有统计学意义(n P0.05)。n 结论:孟鲁司特钠联合复方异丙托溴铵治疗支气管哮喘疗效较好，可显著改善肺功能，降低血清IL-6水平，且未新增不良反应。“,”Objective:To investigate the efficacy of montelukast sodium combined with compound ipratropium bromide in the treatment of bronchial asthma.Methods:A total of 73 patients with bronchial asthma admitted to Xinxiang First People’s Hospital from March 2017 to January 2019 were selected. According to the random number table method, they were divided into the observation group (n n=38) and control group (n n=35). The control group was treated with compound ipratropium bromide, and the observation group was treated with montelukast sodium on the basis of treatment of the control group. Both groups were treated for 1 month. The clinical efficacy and lung function assessed by forced expiratory volume in 1 second (FEV1), forced vital capacity (FVC), peak expiratory flow (PEF), forced expiratory vital capacity per second rate (FEV1/FVC), and changes in serum interleukin-6(IL-6) level of the two groups were monitored.n Results:The total effective rate of treatment in the observation group was 94.74%(36/38), significantly higher than the 74.29% (26/35) in the control group (n P<0.05). After treatment, FEV1, FVC, PEF, and FEV1/FVC in the observation group were higher than those in the control group (n P<0.05). The level of IL-6 in the observation group was lower than that in the control group after treatment (n P0.05).n Conclusions:Montelukast sodium combined with compound ipratropium bromide has good efficacy in the treatment of bronchial asthma, which can significantly improve lung function and reduce serum IL-6 level without new adverse reactions.